Search

Your search keyword '"Harrison, Pille"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Harrison, Pille" Remove constraint Author: "Harrison, Pille"
46 results on '"Harrison, Pille"'

Search Results

1. Genetic susceptibility and severity factors in rheumatoid arthritis

2. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

12. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population

16. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

17. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

20. Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

21. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

22. Filgotinib, an oral JAK1 selective inhibitor, is effective in combination with methotrexate and as monotherapy in patients with active rheumatoid arthritis: results from two Phase 2B studies (DARWIN 1 and DARWIN 2)

24. Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces gut Tissue PSTAT3 in Crohn’s Disease Patients

25. Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

26. Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn’s Disease

28. 812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis

30. Filgrastiimi ja somatropiini sisaldavad sarnased bioloogilised ravimid

31. Sarnased bioloogilised ravimid – epoetiinid

32. Sarnased bioloogilised ravimid

34. Identification of novel RA susceptibility loci at chromosomes 10p15, 12q13 and 22q13

36. Su1930 - Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

37. Su1920 - Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn’s Disease

38. Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease

39. The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets

40. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13.

41. Rheumatoid arthritis association at 6q23.

42. Su1930 - Maintenance of Clinical Effect in Patients with Moderateto-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study.

45. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.

46. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.

Catalog

Books, media, physical & digital resources